-- WellPoint says new hepatitis c drug prices are too high
-- 
-- Fri Mar 21, 2014 12:20PM EDT
-- None



March 21 (Reuters) - The head of WellPoint Inc's <WLP.N> commercial business said on Friday that the price of new hepatitis c drugs, which are made by Gilead Sciences Inc <GILD.O> and Johnson and Johnson <JNJ.N>, are too high.

Ken Goulet, speaking to investors, said the company is working with regulators and drug manufacturers to bring these prices down to a "reasonable" level. He said that as of mid-February the company had filled 100 prescriptions for commercial members.